The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting

S. P. Menting; J. M. P. A. van den Reek; E. M. Baerveldt; E. M. G. J. de Jong; E. P. Prens; L. L. A. Lecluse; G. J. Wolbink; D. van der Kleij; Ph I. Spuls; T. Rispens

doi:https://doi.org/10.1111/bjd.13834

The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting

S. P. Menting, J. M. P. A. van den Reek, E. M. Baerveldt, E. M. G. J. de Jong, E. P. Prens, L. L. A. Lecluse, G. J. Wolbink, D. van der Kleij, Ph I. Spuls, T. Rispens

Research output: Contribution to journal › Comment/Letter to the editor › Academic

36 Citations (Scopus)

Abstract

Several therapeutic antibodies are available for the treatment of chronic plaque type psoriasis. Ustekinumab (a monoclonal IL12/23 antagonist) is one of these antibodies (1) and it is currently being investigated for other indications. For adalimumab (a monoclonal tumour necrosis factor α antagonist) a positive correlation has been observed between adalimumab trough levels and clinical efficacy, both showing a negative correlation with anti-drug antibodies (ADA) to adalimumab (present in 49% of patients) (2). In rheumatoid arthritis, a therapeutic range for adalimumab trough level has been established, which can eventually lead to a more personalised way of administering adalimumab (3). This article is protected by copyright. All rights reserved

Original language	English
Pages (from-to)	855-857
Journal	British Journal of Dermatology
Volume	173
Issue number	3
DOIs	https://doi.org/10.1111/bjd.13834
Publication status	Published - 2015

Access to Document

https://doi.org/10.1111/bjd.13834

Cite this

Menting, S. P., van den Reek, J. M. P. A., Baerveldt, E. M., de Jong, E. M. G. J., Prens, E. P., Lecluse, L. L. A., Wolbink, G. J., van der Kleij, D., Spuls, P. I., & Rispens, T. (2015). The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting. British Journal of Dermatology, 173(3), 855-857. https://doi.org/10.1111/bjd.13834

@article{d86e5d237de846989ec9b6a029898ee4,

title = "The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting",

abstract = "Several therapeutic antibodies are available for the treatment of chronic plaque type psoriasis. Ustekinumab (a monoclonal IL12/23 antagonist) is one of these antibodies (1) and it is currently being investigated for other indications. For adalimumab (a monoclonal tumour necrosis factor α antagonist) a positive correlation has been observed between adalimumab trough levels and clinical efficacy, both showing a negative correlation with anti-drug antibodies (ADA) to adalimumab (present in 49% of patients) (2). In rheumatoid arthritis, a therapeutic range for adalimumab trough level has been established, which can eventually lead to a more personalised way of administering adalimumab (3). This article is protected by copyright. All rights reserved",

author = "Menting, {S. P.} and {van den Reek}, {J. M. P. A.} and Baerveldt, {E. M.} and {de Jong}, {E. M. G. J.} and Prens, {E. P.} and Lecluse, {L. L. A.} and Wolbink, {G. J.} and {van der Kleij}, D. and Spuls, {Ph I.} and T. Rispens",

year = "2015",

doi = "https://doi.org/10.1111/bjd.13834",

language = "English",

volume = "173",

pages = "855--857",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "3",

}

Menting, SP, van den Reek, JMPA, Baerveldt, EM, de Jong, EMGJ, Prens, EP, Lecluse, LLA, Wolbink, GJ, van der Kleij, D, Spuls, PI & Rispens, T 2015, 'The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting', British Journal of Dermatology, vol. 173, no. 3, pp. 855-857. https://doi.org/10.1111/bjd.13834

The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting. / Menting, S. P.; van den Reek, J. M. P. A.; Baerveldt, E. M. et al.
In: British Journal of Dermatology, Vol. 173, No. 3, 2015, p. 855-857.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting

AU - Menting, S. P.

AU - van den Reek, J. M. P. A.

AU - Baerveldt, E. M.

AU - de Jong, E. M. G. J.

AU - Prens, E. P.

AU - Lecluse, L. L. A.

AU - Wolbink, G. J.

AU - van der Kleij, D.

AU - Spuls, Ph I.

AU - Rispens, T.

PY - 2015

Y1 - 2015

N2 - Several therapeutic antibodies are available for the treatment of chronic plaque type psoriasis. Ustekinumab (a monoclonal IL12/23 antagonist) is one of these antibodies (1) and it is currently being investigated for other indications. For adalimumab (a monoclonal tumour necrosis factor α antagonist) a positive correlation has been observed between adalimumab trough levels and clinical efficacy, both showing a negative correlation with anti-drug antibodies (ADA) to adalimumab (present in 49% of patients) (2). In rheumatoid arthritis, a therapeutic range for adalimumab trough level has been established, which can eventually lead to a more personalised way of administering adalimumab (3). This article is protected by copyright. All rights reserved

AB - Several therapeutic antibodies are available for the treatment of chronic plaque type psoriasis. Ustekinumab (a monoclonal IL12/23 antagonist) is one of these antibodies (1) and it is currently being investigated for other indications. For adalimumab (a monoclonal tumour necrosis factor α antagonist) a positive correlation has been observed between adalimumab trough levels and clinical efficacy, both showing a negative correlation with anti-drug antibodies (ADA) to adalimumab (present in 49% of patients) (2). In rheumatoid arthritis, a therapeutic range for adalimumab trough level has been established, which can eventually lead to a more personalised way of administering adalimumab (3). This article is protected by copyright. All rights reserved

U2 - https://doi.org/10.1111/bjd.13834

DO - https://doi.org/10.1111/bjd.13834

M3 - Comment/Letter to the editor

C2 - 25865153

SN - 0007-0963

VL - 173

SP - 855

EP - 857

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 3

ER -